Diabetes & Nephrology News, Research Studies | Clinical Treatment Articles



Apabetalone Gets Breakthrough Tx Designation for MACE Prevention

The FDA has granted Breakthrough Therapy designation to apabetalone (Resverlogix Corp) in combination with standard of care therapy, including high-intensity statins, for the secondary prevention of major adverse cardiac events (MACE) in patients with type 2 diabetes mellitus and recent acute coronary syndrome.

Trulicity Approved to Reduce Risk of Major Adverse Cardiovascular Events

The FDA has approved Trulicity (dulaglutide; Lilly) to reduce the risk of major adverse cardiovascular events (MACE; cardiovascular death, nonfatal myocardial infarction [MI], or nonfatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.
Next post in Diabetes